Published in Nat Commun on January 01, 2013
BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol (2014) 3.68
Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature (2016) 3.05
Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet (2014) 2.86
Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science (2015) 2.37
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst (2014) 2.29
Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med (2016) 2.15
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer (2014) 2.10
Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science (2015) 1.91
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab (2014) 1.71
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab (2014) 1.52
TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol (2014) 1.49
The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing. Hum Mutat (2015) 1.46
Recurrent somatic mutations in regulatory regions of human cancer genomes. Nat Genet (2015) 1.45
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget (2014) 1.40
FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer. Genome Biol (2014) 1.36
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. J Invest Dermatol (2014) 1.21
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch (2014) 1.09
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. J Exp Clin Cancer Res (2014) 1.08
Role of Telomeres and Telomerase in Aging and Cancer. Cancer Discov (2016) 1.03
A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression. Genome Biol (2015) 1.02
TERT promoter mutations in thyroid cancer. Endocr Relat Cancer (2016) 1.01
Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes Dev (2015) 1.01
Diverse modes of genomic alteration in hepatocellular carcinoma. Genome Biol (2014) 0.99
Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab (2015) 0.98
TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. Oncotarget (2015) 0.96
Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer (2015) 0.96
Cancer whole-genome sequencing: present and future. Oncogene (2015) 0.95
Cell populations can use aneuploidy to survive telomerase insufficiency. Nat Commun (2015) 0.95
TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS One (2013) 0.95
Prognostic biomarkers in thyroid cancer. Virchows Arch (2014) 0.95
Hereditary melanoma: Update on syndromes and management: Emerging melanoma cancer complexes and genetic counseling. J Am Acad Dermatol (2016) 0.94
TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas. Oncotarget (2014) 0.94
The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr Relat Cancer (2014) 0.94
TERT promoter mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma. Oncotarget (2014) 0.93
BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget (2016) 0.93
Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. Oncotarget (2014) 0.93
Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro Oncol (2015) 0.92
The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations. EMBO Mol Med (2016) 0.91
TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas. PLoS One (2014) 0.91
Telomere biology and translational research. Transl Res (2013) 0.90
Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Arch (2014) 0.90
Understanding TERT Promoter Mutations: A Common Path to Immortality. Mol Cancer Res (2016) 0.90
Identification of High-Impact cis-Regulatory Mutations Using Transcription Factor Specific Random Forest Models. PLoS Comput Biol (2015) 0.90
Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J Clin Endocrinol Metab (2015) 0.89
OncoCis: annotation of cis-regulatory mutations in cancer. Genome Biol (2014) 0.89
Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol (2014) 0.87
Telomere-regulating genes and the telomere interactome in familial cancers. Mol Cancer Res (2014) 0.87
Reactivation of telomerase in cancer. Cell Mol Life Sci (2016) 0.87
NCG 5.0: updates of a manually curated repository of cancer genes and associated properties from cancer mutational screenings. Nucleic Acids Res (2015) 0.86
Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma. J Clin Endocrinol Metab (2014) 0.86
TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis (2015) 0.86
Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocr Relat Cancer (2014) 0.85
Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol (2016) 0.83
Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. J Invest Dermatol (2016) 0.83
Differentiated thyroid cancer in patients with resistance to thyroid hormone syndrome. A novel case and a review of the literature. Front Mol Biosci (2014) 0.83
Telomere maintenance mechanisms in cancer: clinical implications. Curr Pharm Des (2014) 0.82
Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet (2017) 0.82
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med (2016) 0.82
ORegAnno 3.0: a community-driven resource for curated regulatory annotation. Nucleic Acids Res (2015) 0.82
Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Neuro Oncol (2016) 0.82
LARVA: an integrative framework for large-scale analysis of recurrent variants in noncoding annotations. Nucleic Acids Res (2015) 0.81
Telomere and Telomerase Therapeutics in Cancer. Genes (Basel) (2016) 0.81
Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs). Eur J Hum Genet (2014) 0.81
Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer. BMC Med (2016) 0.81
Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Arch (2015) 0.80
Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Lab Invest (2016) 0.80
Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene. Genes (Basel) (2016) 0.79
Evolving Molecular Genetics of Glioblastoma. Chin Med J (Engl) (2016) 0.79
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications. Genes (Basel) (2016) 0.79
Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression. J Clin Invest (2016) 0.79
Molecular Signature of Indeterminate Thyroid Lesions: Current Methods to Improve Fine Needle Aspiration Cytology (FNAC) Diagnosis. Int J Mol Sci (2017) 0.78
Telomerase reactivation in cancers: Mechanisms that govern transcriptional activation of the wild-type vs. mutant TERT promoters. Transcription (2016) 0.78
The search for cis-regulatory driver mutations in cancer genomes. Oncotarget (2015) 0.78
Genotyping of cutaneous melanoma. Chin Clin Oncol (2014) 0.78
TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas. Oncotarget (2016) 0.78
A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. Nat Genet (2017) 0.77
A six-genotype genetic prognostic model for papillary thyroid cancer. Endocr Relat Cancer (2016) 0.77
Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. J Control Release (2016) 0.77
Global inference of disease-causing single nucleotide variants from exome sequencing data. BMC Bioinformatics (2016) 0.77
A novel truncated form of HMGA2 in tumors of the ovaries. Oncol Lett (2016) 0.77
Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma. Cell Death Dis (2016) 0.77
Functional evaluation of TERT-CLPTM1L genetic variants associated with susceptibility of papillary thyroid carcinoma. Sci Rep (2016) 0.77
Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. Oncotarget (2016) 0.77
Challenges in identifying cancer genes by analysis of exome sequencing data. Nat Commun (2016) 0.77
A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol (2016) 0.77
Integrative analysis reveals clinical phenotypes and oncogenic potentials of long non-coding RNAs across 15 cancer types. Oncotarget (2016) 0.77
Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. Diagn Pathol (2016) 0.77
Genome-wide prediction of cancer driver genes based on SNP and cancer SNV data. Am J Cancer Res (2014) 0.77
In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF (V600E) mutation. Virchows Arch (2016) 0.76
Development and characterization of six new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab (2014) 0.76
TERT promoter mutations are a rare event in gastrointestinal stromal tumors. Springerplus (2015) 0.75
Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling Networks. Biomed Res Int (2016) 0.75
The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer (2017) 0.75
Epigenomic annotation of noncoding mutations identifies mutated pathways in primary liver cancer. PLoS One (2017) 0.75
Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations. J Clin Invest (2017) 0.75
Current Insights to Regulation and Role of Telomerase in Human Diseases. Antioxidants (Basel) (2017) 0.75
Taking the brakes off telomerase. Elife (2015) 0.75
Planning cancer control in Latin America and the Caribbean. Lancet Oncol (2013) 8.43
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
The banana (Musa acuminata) genome and the evolution of monocotyledonous plants. Nature (2012) 3.53
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene (2003) 3.34
Role of sulphuric acid, ammonia and galactic cosmic rays in atmospheric aerosol nucleation. Nature (2011) 2.65
A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology (2003) 2.39
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol (2004) 2.21
The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors. Mod Pathol (2011) 2.08
Definitions of bullying: a comparison of terms used, and age and gender differences, in a fourteen-country international comparison. Child Dev (2002) 2.00
The diversity present in 5140 human mitochondrial genomes. Am J Hum Genet (2009) 1.90
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab (2014) 1.71
Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch (2005) 1.62
Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. Am J Pathol (2002) 1.61
Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol (2004) 1.59
Training and accreditation in cardiovascular magnetic resonance in Europe: a position statement of the working group on cardiovascular magnetic resonance of the European Society of Cardiology. Eur Heart J (2011) 1.53
BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.52
How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer. J Thyroid Res (2011) 1.46
Carcinoma of the thyroid with ewing family tumor elements and favorable prognosis: report of a second case. Int J Surg Pathol (2013) 1.46
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid (2007) 1.41
Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol (2004) 1.39
Idiopathic perforation of the gallbladder: a novel differential diagnosis of acute abdomen. J Pediatr Gastroenterol Nutr (2002) 1.33
Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. Virchows Arch (2001) 1.30
Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem (2002) 1.30
A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. Eur J Cancer (2009) 1.24
Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch (2003) 1.24
STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A (2012) 1.23
Metastatic tumours to the oral cavity: a survival study with a special focus on gingival metastases. J Clin Periodontol (2009) 1.22
Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res (2007) 1.22
Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Curr Genomics (2011) 1.18
Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics (2013) 1.17
Helicobacter pylori infection induces genetic instability of nuclear and mitochondrial DNA in gastric cells. Clin Cancer Res (2009) 1.14
Oncocytic lesions of the thyroid, kidney, salivary glands, adrenal cortex, and parathyroid glands. Int J Surg Pathol (2014) 1.10
Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch (2014) 1.09
SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A Randomized Controlled Crossover Study. Retina (2015) 1.08
mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab (2012) 1.08
Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res (2010) 1.08
Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. Oncogene (2005) 1.07
Ciliary body medulloepithelioma: analysis of 41 cases. Ophthalmology (2013) 1.06
Sclerosing epithelioid fibrosarcoma primary of the bone. Int J Surg Pathol (2002) 1.05
Loss of heterozygosity and promoter methylation, but not mutation, may underlie loss of TFF1 in gastric carcinoma. Lab Invest (2002) 1.05
Two evolutionarily distinct classes of paleopolyploidy. Mol Biol Evol (2013) 1.05
Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression. Am J Surg Pathol (2003) 1.04